Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma

Modern Pathology

Volumn 24, Issue 2, 2011, Pages 201-208

  Peiró, Gloria ^a   Adrover, Encarna ^a   Sánchez Tejada, Laura ^a   Lerma, Enrique ^b   Planelles, María ^a   Sánchez Payá, José ^a   Aranda, Francisco I ^a   Giner, Daniel ^a   Gutiérrez Avĩó, Francisco J ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

early breast carcinoma; IGF1R; immunophenotypes; prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DNA MICROARRAY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IGF1R GENE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; BREAST NEOPLASMS; CARCINOMA; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79551643709     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.191     Document Type: Article

References (46)

1. Perou CM, Sorlie T, Eisen MB, et al Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
2. Sorlie T, Tibshirani R, Parker J, et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
3. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007;7:791-799.
4. Clarke M, Collins R, Darby S, et al Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Livi L, Paiar F, Saieva C, et al Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 2007;82:287-293.
7. Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:51-57.
8. Punglia RS, Morrow M, Winer EP, et al Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399-2405.
9. Haffty BG, Yang Q, Reiss M, et al Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
10. Nguyen PL, Taghian AG, Katz MS, et al Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-2378.
11. Smid M, Wang Y, Zhang Y, et al Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-3114.
12. Parker JS, Mullins M, Cheang MC, et al Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
13. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009; 4:54-72.
14. Brooks PC, Klemke RL, Schon S, et al Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 1997;99:1390-1398.
15. Brodt P, Fallavollita L, Khatib AM, et al Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 2001;276: 33608-33615.
16. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-207.
17. Ouban A, Muraca P, Yeatman T, et al Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003;34:803-808.
18. Al Sarakbi W, Chong Y, Williams S, et al The mRNA expression of IGF-1 and IGF-1R in human breast cancer: association with clinico-pathological parameters. J Carcinog 2006;5:16.
19. Chong YM, Colston K, Jiang WG, et al The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 2006;99:275-288.
20. Papa V, Gliozzo B, Clark GM, et al Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53: 3736-3740.
21. Schnarr B, Strunz K, Ohsam J, et al Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 2000;89:506-513.
22. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:67-79.
23. Shimizu C, Hasegawa T, Tani Y, et al Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004;35:1537-1542.
24. Gee JM, Robertson JF, Gutteridge E, et al Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12:S99-S111.
25. Ueda S, Tsuda H, Sato K, et al Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci 2006;97:597-604.
26. Creighton CJ, Casa A, Lazard Z, et al Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-4085.
27. Law JH, Habibi G, Hu K, et al Phosphorylated insulinlike growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-10246.
28. Lam L, Hu X, Aktary Z, et al Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. Breast Cancer Res Treat 2009;118:605-621.
29. Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol 2009;5:43-50.
30. Peiro G, Benlloch S, Sanchez-Tejada L, et al Low activation of insulin-like growth factor 1-receptor (IGF1R) is associated with local recurrence in early breast carcinoma. Breast Cancer Res Treat 2009;117: 433-441.
31. Peiro G, Aranda FI, Adrover E, et al Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: prognostic relevance. Hum Pathol 2007;38:26-34.
32. Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004;23:385-394.
33. Happerfield LC, Miles DW, Barnes DM, et al The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 1997;183:412-417.
34. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-2610.
35. Chan TW, Pollak M, Huynh H. Inhibition of insulinlike growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182 780. Clin Cancer Res 2001;7:2545-2554.
36. Brockdorff BL, Heiberg I, Lykkesfeldt AE. Resistance to different antiestrogens is caused by different multifactorial changes and is associated with reduced expression of IGF receptor Ialpha. Endocr Relat Cancer 2003;10:579-590.
37. Lerma E, Peiro G, Ramon T, et al Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/ neu (basal-like breast carcinomas). Mod Pathol 2007;20:1200-1207.
38. Adelaide J, Finetti P, Bekhouche I, et al Integrated profiling of basal and luminal breast cancers. Cancer Res 2007;67:11565-11575.
39. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005;23:1631-1635.
40. Paik S, Tang G, Shak S, et al Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
41. Loi S, Haibe-Kains B, Desmedt C, et al Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246.
42. Peiro G, Adrover E, Aranda FI, et al Prognostic implications of HER-2 status in steroid receptorpositive, lymph node-negative breast carcinoma. Am J Clin Pathol 2007;127:780-786.
43. Turner BC, Haffty BG, Narayanan L, et al Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57:3079-3083.
44. Nuyten DS, Kreike B, Hart AA, et al Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8:R62.
45. Wang Y, Klijn JG, Zhang Y, et al Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 2005;365: 671-679.
46. Wang Y, Connolly JL, Hu R, et al Expression of insulinlike growth factor-i receptor (IGF-IR) in normal breast tissue and breast cancer risk: results from the Nurses' Health Study. Mod Pathol 2009;22:73A.